In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2

Trina Racine; Mélanie Denizot; Delphine Pannetier; Ludovic Nguyen; Anaïs Pasquier; Hervé Raoul; Jean François Saluzzo; Gary Kobinger; Francisco Veas; Cécile H. Herbreteau

doi:10.1093/infdis/jiz068

In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)₂

Trina Racine, Mélanie Denizot, Delphine Pannetier, Ludovic Nguyen, Anaïs Pasquier, Hervé Raoul, Jean François Saluzzo, Gary Kobinger, Francisco Veas, Cécile H. Herbreteau

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)₂, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)₂ showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)₂ intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)₂ offers a potentially efficient therapeutic approach against EBOV disease in humans.

Original language	English (US)
Article number	jiz068
Pages (from-to)	41-45
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	220
Issue number	1
DOIs	https://doi.org/10.1093/infdis/jiz068
State	Published - Jun 5 2019
Externally published	Yes

Keywords

Ebola
F(ab′) fragments
equine
immunoglobulins

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/infdis/jiz068

Cite this

@article{1049470510814aa780d0247c388b0169,

title = "In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2",

abstract = "There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)2 offers a potentially efficient therapeutic approach against EBOV disease in humans.",

keywords = "Ebola, F(ab′) fragments, equine, immunoglobulins",

author = "Trina Racine and M{\'e}lanie Denizot and Delphine Pannetier and Ludovic Nguyen and Ana{\"i}s Pasquier and Herv{\'e} Raoul and Saluzzo, {Jean Fran{\c c}ois} and Gary Kobinger and Francisco Veas and Herbreteau, {C{\'e}cile H.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019.",

year = "2019",

month = jun,

day = "5",

doi = "10.1093/infdis/jiz068",

language = "English (US)",

volume = "220",

pages = "41--45",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - In Vitro Characterization and in Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)2

AU - Racine, Trina

AU - Denizot, Mélanie

AU - Pannetier, Delphine

AU - Nguyen, Ludovic

AU - Pasquier, Anaïs

AU - Raoul, Hervé

AU - Saluzzo, Jean François

AU - Kobinger, Gary

AU - Veas, Francisco

AU - Herbreteau, Cécile H.

PY - 2019/6/5

Y1 - 2019/6/5

N2 - There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)2 offers a potentially efficient therapeutic approach against EBOV disease in humans.

AB - There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)2, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)2 showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)2 intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)2 offers a potentially efficient therapeutic approach against EBOV disease in humans.

KW - Ebola

KW - F(ab′) fragments

KW - equine

KW - immunoglobulins

UR - http://www.scopus.com/inward/record.url?scp=85067441008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067441008&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiz068

DO - 10.1093/infdis/jiz068

M3 - Article

C2 - 30852585

AN - SCOPUS:85067441008

SN - 0022-1899

VL - 220

SP - 41

EP - 45

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 1

M1 - jiz068

ER -